Navigation Links
Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center
Date:5/27/2008

Summary: Exiqon A/S Today Announces That it has Entered Into a

Collaborative Research Agreement With The University of Texas M. D. Anderson Cancer Center to Develop microRNA Based Biomarkers for Breast

Cancer

VEDBAEK, Denmark, May 27 /PRNewswire-FirstCall/ -- Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announces that it has signed a collaborative research agreement with the Kleberg Center for Molecular Markers at The University of Texas M. D. Anderson Cancer Center to discover microRNA based biomarkers for breast cancer.

Under this agreement, Exiqon will use its miRCURY(TM) LNA(TM) products to discover microRNA biomarkers.

Specifically, the project focuses on identifying miRNA expression signatures associated with relapse and progression of breast cancer, and to develop and validate diagnostic tools that will guide patient management.

"This collaboration is another important step for Exiqon on our path to develop microRNA based cancer diagnostics. M. D. Anderson is one of the leading cancer centers in the world, and through this collaboration we bring exceptional clinical expertise and strong gene expression technology together to develop next generation molecular diagnostics," said Lars Kongsbak, president and CEO of Exiqon. "This agreement with the M. D. Anderson will enable us to develop diagnostic products based on our LNA(TM) technology to support major advances in cancer research and cancer diagnostics."

"This collaboration with Exiqon to develop microRNA biomarkers is a part of our efforts to achieve the goal of the change of patient treatment. This collaboration is part of our 'Systems' approach to unify, DNA, RNA and protein approaches in understanding and developing molecular markers for treatment changes and our effort in developing microRNA based molecular marker panels with different industry leaders in the microRNA field,
'/>"/>

SOURCE Exiqon A/S
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
3. UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials
4. Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study
5. Allegheny General Hospital Performs First Liver Transplant
6. Research Team Clones Genes Responsible for Amino Acid Absorption
7. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
8. Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting
9. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
10. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
11. Cardiovascular Researchers Use MEDIHONEY(TM) on Sternal Infections Following Open-Heart Procedures

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...BUQUERQUE, N.M., Dec. 1 Exagen Dia... that discovers, develops and markets proprietary ...Scott Glenn as chairman of the company,s board of ... to joining Exagen, Glenn was managing partner of ... of successful biomedical companies including Prom...
(Date:12/1/2009)..., BEIJING, Dec. 1 /PRNewswire-Asia/ -- Sino...r of biopharmaceutical products in China, announce...rder for its H1N1 vaccine, PANFLU.1(TM),from Chin...y for the national,purchase plan. Under this purch...ional one million doses of PANFLU.1 (TM) (15ug/0.5...
(Date:12/1/2009)..., REDWOOD CITY, Calif., Dec. 1 Cod...ationship and the signing of its second agreement ..., the world,s largest generic drug manufacturer. ...eutical products. Codexis announced an earlier ag...w agreement, Teva will use Codexis biocatalysis te...
Breaking Medicine Technology:Scott Glenn Joins Exagen Diagnostics as Chairman and CEO 2Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government 2Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government 3Codexis Expands Collaboration with Teva 2Newly found DNA catalysts cleave DNA with water molecule 9589 1Newly found DNA catalysts cleave DNA with water molecule 9589 2Researchers develop new more sensitive assay for detecting DNA methylation in colon cancer 9586 1Researchers develop new more sensitive assay for detecting DNA methylation in colon cancer 9586 2Researchers develop new more sensitive assay for detecting DNA methylation in colon cancer 9586 3Web Is Becoming One Stop Shopping for Health Help 54591 1Web Is Becoming One Stop Shopping for Health Help 54591 2Web Is Becoming One Stop Shopping for Health Help 54591 3
...s of Arimidex (anastrozole) over tamoxifen at prev...crease over time - even four years after ...ec. 14 New data from ATAC*, one of the,world,s la...l women with,early breast cancer, reinforce that a...ee, for longer. For the first time, anastrozole ha...
...ON, Mass., Dec. 18 Alseres,Pharmaceuticals, Inc.,...olled,the first subject in the initial stage of th... (POET-2) Phase III clinical trial program. This,s...Birmingham trial site,under the direction of Princ...nd Chairman of the Department of Neurology., ALTR...
Other Medicine Technology:Video: New Results From One of the World's Largest Breast Cancer Trials Herald Hope for Thousands of Women 2Video: New Results From One of the World's Largest Breast Cancer Trials Herald Hope for Thousands of Women 3Video: New Results From One of the World's Largest Breast Cancer Trials Herald Hope for Thousands of Women 4Video: New Results From One of the World's Largest Breast Cancer Trials Herald Hope for Thousands of Women 5Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program 2Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program 3Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program 4Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program 5
(Date:12/1/2009)... , SOUTHFIELD, Mich., Dec. 1 /PRNewswire-First...SE: FMR ) ("First Mercury" or the "Company") ann...f Directors declared a quarterly cash dividend of ...shareholders of record at the close of business on...inancial Corporation ,, First Mercury Financia...
(Date:12/1/2009)... identify those who would benefit from liver surge...Y, Dec. 1 (HealthDay News) -- A CT scan of liver t...y help predict overall survival after chemotherapy...stin) to cytotoxic chemotherapy has been shown to ...ectal cancer and to produce better results in pati...
(Date:12/1/2009)...LADELPHIA (December 1, 2009) Wistar Institute re... Pennsylvania and New York University have identif...ate early-stage lung tumors in people at high risk...ed online December 1 in Cancer Research , a journ..., could lead to a simple blood test to detect lung...
(Date:12/1/2009)... Ever thought you could quit s...vin Arthur Smith,s groundbreaking new system for q...ermanent. In just twenty eight days your cravings ... (PRWEB) December 1, 2009 -...g her eight-year addiction to nicotine, smoking at...
(Date:12/1/2009)... , LEHIGH VALLEY, Pa., Dec. 1 /PRNewswire-Firs...t has completed the previously announced sale of t...s, marketed under the Airthane® and Versathan... subsidiary of global polyurethane chemicals produ...Products, manufacturing facility in Paulsboro, N.J...
Breaking Medicine News(10 mins):Health News:CT Scan May Predict Colon Cancer Survival 2Health News:Wistar-led research team discovers genetic pattern that indicates early-stage lung cancer 2Health News:Wistar-led research team discovers genetic pattern that indicates early-stage lung cancer 3Health News:Former Cigarette Dealer Sells Business in Order to Fund Quit Smoking Book 2Health News:Former Cigarette Dealer Sells Business in Order to Fund Quit Smoking Book 3Health News:Air Products Completes Sale of Polyurethane Pre-Polymers Business to COIM USA 2
...,Corporation (Nasdaq: SMTS ) announced today that... to repurchase up to $15 million of its common,sha...e open market or in,privately negotiated transacti...186 common shares outstanding as of April,2, 2008....
... for lung invasion, study shows , , THURSD...nd to spread to specific tissues, and now research...pens. , Working with breast tumors, Joan Massague,...ling "relay" that enables the cancer to molecularl...
...b &,Ellis Company (NYSE: GBE ), a leading real es...report released today that aging baby boomers and,...fuel demand for,healthcare properties over the nex...llis, Chief Economist and author of the,report., ...
...roviders, and Patients, WASHINGTON, April 3, 2008...rganizations (AAPPO), in collaboration,with DMAA: ... a diabetes,toolkit for PPO executives to help hea...: http://www.newscom.com/cgi-bin/prnh/20060126/CL...
...n A. Clements is the recipient of the 2008 Pollin ...to our understanding of how lungs hold air, and to...piratory distress syndrome (RDS) in infants. Once ...t international award for pediatric research, reco...
...a Hall Institute, Professor Suzanne Cory, is one o...omson Scientific Citation Awards announced at the ...tific, a US-based international information analys...per their published research has had over a period...
Other Medicine News:Health News:Somanetics Announces Share Repurchase Program 2Health News:Molecular Cause of Breast Cancer Metastasis Discovered 2Health News:Molecular Cause of Breast Cancer Metastasis Discovered 3Health News:Aging Baby Boomers Will Drive Demand for Healthcare Properties Over Next Decade, Grubb & Ellis Report Reveals 2Health News:Aging Baby Boomers Will Drive Demand for Healthcare Properties Over Next Decade, Grubb & Ellis Report Reveals 3Health News:Aging Baby Boomers Will Drive Demand for Healthcare Properties Over Next Decade, Grubb & Ellis Report Reveals 4Health News:Aging Baby Boomers Will Drive Demand for Healthcare Properties Over Next Decade, Grubb & Ellis Report Reveals 5Health News:AAPPO Releases Diabetes Toolkit to Spur Action on Better Diabetes Care 2Health News:AAPPO Releases Diabetes Toolkit to Spur Action on Better Diabetes Care 3Health News:Pollin Pediatric Research Prize awarded for discovery of lifesaving treatment of RDS 2Health News:Pollin Pediatric Research Prize awarded for discovery of lifesaving treatment of RDS 3Health News:Pollin Pediatric Research Prize awarded for discovery of lifesaving treatment of RDS 4Health News:Professor Suzanne Cory honored with national citation award 2
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
Medicine Products: